论文部分内容阅读
目的:观察更昔洛韦联合异甘草酸镁治疗婴儿巨细胞病毒(CMV)肝炎的临床疗效。方法:选择在我院住院治疗的巨细胞病毒肝炎患儿68例,随机分为治疗组38例和对照组30例。治疗组给予更昔洛韦联合异甘草酸镁治疗,对照组单用更昔洛韦治疗,两组其他辅助治疗相同,疗程均为6周。详细记录治疗前后患儿症状、体征、肝功能、肾功能、电解质及血尿常规,同时记录治疗过程中的不良反应。结果:两组患儿治疗后肝功能生化指标与治疗前比较差异有统计学意义(P<0.05);两组治疗后各项生化指标下降程度比较差异有统计学意义(P<0.05),治疗组明显优于对照组;治疗组总有效率89.5%,对照组总有效率43.4%,两组比较差异有统计学意义(P<0.05);治疗组出现的不良反应例数明显少于对照组。结论:更昔洛韦联合异甘草酸镁治疗婴儿巨细胞病毒肝炎疗效显著,而且不良反应少,值得临床推广。
Objective: To observe the clinical efficacy of ganciclovir combined with magnesium isoglycyrrhizinate in the treatment of infant cytomegalovirus (CMV) hepatitis. Methods: Sixty-eight children with cytomegalovirus hepatitis treated in our hospital were randomly divided into treatment group (n = 38) and control group (n = 30). The treatment group was given ganciclovir combined with magnesium isoglycyrrhizinate, while the control group was treated with ganciclovir alone. The other two adjuvant therapies were the same, both for 6 weeks. Detailed records before and after treatment in children with symptoms, signs, liver function, renal function, electrolytes and hematuria routine, while recording the adverse reactions in the course of treatment. Results: The biochemical indexes of liver function after treatment in both groups were significantly different from those before treatment (P <0.05). There was significant difference in the biochemical indexes between the two groups after treatment (P0.05) The total effective rate was 89.5% in the treatment group and 43.4% in the control group, with significant difference between the two groups (P <0.05). The number of adverse reactions in the treatment group was significantly less than that in the control group . Conclusion: Ganciclovir combined with magnesium isoglycyrrhizinate in the treatment of infantile cytomegalovirus hepatitis has significant curative effect with less adverse reactions and is worthy of clinical promotion.